- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05974150
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia (AML) Using Remote Symptom Monitoring
The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment.
Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic patient reported outcome (PRO) surveys are collected from the patients using the Carevive platform for a minimum of 12 weeks. Patients may continue weekly surveys as long as they are receiving treatment.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: JULIE SCOTT, MSN
- Phone Number: 8778423210
- Email: Julie.Scott@Carevive.com
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Recruiting
- Yale Cancer Center
-
Contact:
- Kim Blenman
- Email: kim.blenman@yale.edu
-
Principal Investigator:
- Kim Blenman
-
-
Illinois
-
Evanston, Illinois, United States, 31024
- Recruiting
- NorthShore University Health System
-
Contact:
- Michele Britto
- Email: mbritto@northshore.org
-
Principal Investigator:
- Nicklas Pfanzelter
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Recruiting
- Univeristy of North Carolina at Chapel Hill
-
Contact:
- Miriam Perez
- Email: miriam_perez@med.unc.edu
-
Principal Investigator:
- Ashley Bryant, Ph.D
-
Durham, North Carolina, United States, 27707
- Recruiting
- Duke
-
Contact:
- Kris Herring, Ph.D.
- Email: kris.herring@duke.edu
-
Principal Investigator:
- Thomas Leblanc, MD
-
-
Ohio
-
Canton, Ohio, United States, 44708
- Recruiting
- Cleveland Clinic Mercy Hospital
-
Principal Investigator:
- Mitchell Haut, MD
-
Contact:
- Janet Muckley
- Email: MUCKLEJ@ccf.org
-
Cleveland, Ohio, United States, 44106
- Recruiting
- University Hospitals Seidman Cancer Center
-
Contact:
- Jill Severino-Powell, MSN
- Email: Jill.Severino-Powell@UHhospitals.org
-
Principal Investigator:
- Alberto Montero, MD
-
Massillon, Ohio, United States, 44646
- Recruiting
- Tri-County Hematology & Oncology Associates, Inc.
-
Principal Investigator:
- Nagaprasad Nagajothi, MD
-
Contact:
- Janet Muckley
- Email: MUCKLEJ@ccf.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- All participants must be 18 years of age or older.
- Subjects may be any stage and anywhere in the treatment continuum.
- Subject participants must have a diagnosis of a breast, lung, AML, ovarian cancer or multiple myeloma.
- Subjects must be able to complete on-line surveys using a cell phone, tablet, or computer.
- All participants must be able to understand English.
Exclusion Criteria:
- Any patient who cannot understand written or spoken English.
- Any patient without the ability to complete on-line surveys using a cell phone, tablet, or computer.
- Any patient on a treatment clinical trial.
- Any prisoner and/or other vulnerable persons as defined by NIH (45 CFR 46, Subpart B, C and D).
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Create Data Set
Time Frame: 1 year
|
The goal of this registry is to create a data set from real world clinical and patient reported data collected using an electronic care planning system (CPS) that is used in routine care for cancer patients on active treatment
|
1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
Other Study ID Numbers
- OPT-IN Carevive Registry
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Web based survey
-
Unita Complessa di Ostetricia e GinecologiaCompletedCOVID-19 | Coronavirus Infection | COVID | Coronavirus | Transgender PersonsItaly
-
University of South FloridaUniversity of Miami; National Institutes of Health (NIH); University of KansasCompletedAmyotrophic Lateral Sclerosis | Primary Lateral Sclerosis | Progressive Muscular Atrophy | Hereditary Spastic Paraplegia
-
University of South FloridaUniversity of Miami; University of Alabama at Birmingham; Icahn School of Medicine... and other collaboratorsCompletedPorphyriasUnited States
-
University of South FloridaNational Institutes of Health (NIH); Rare Diseases Clinical Research NetworkCompletedOsteogenesis Imperfecta | Brittle Bone DisordersUnited States
-
University of South FloridaNational Institute of Neurological Disorders and Stroke (NINDS); University... and other collaboratorsCompletedCarpal Tunnel Syndrome | Charcot-Marie-Tooth Disease | Inherited Peripheral NeuropathyUnited States
-
University of South FloridaNational Institutes of Health (NIH); Rare Diseases Clinical Research NetworkCompletedOsteogenesis Imperfecta | Brittle Bone DisordersUnited States
-
University Hospital, CaenINSERM UMR U1075 Comète GIP Cyceron, unicaen, Caen NormandieRecruiting
-
D'Or Institute for Research and EducationConselho Nacional de Desenvolvimento Científico e TecnológicoActive, not recruitingDepression | Covid19 | Burnout, Professional | Stress Disorders, Post-Traumatic | Compassion Fatigue | AnxietyBrazil
-
Assiut UniversityCompletedCOVID-19 | Sleep Quality | General HealthEgypt
-
GlaxoSmithKlineCompleted